7 results about "Midkine" patented technology

The present invention provides a method for detecting the presence of or risk of bladder cancer in a female patient, the method comprising the steps of: detecting the presence of a biomarker panel in a sample isolated from a female patient, the biomarker panel comprising IL-13 and IL-12p70 and one or more biomarkers selected from the group consisting of BTA, midkine, PAI-1 / tPA, 8OHdG, CEA, CK18, Fibrillin, Creatinine, CXCL16, Cystatin B, Cystatin C, d-dimer, EGF, FAS, HAD, IL-1a, IL-1b, IL-4, IL-6, IL-7, IL-8, MCP-1, Microalbumin, MMP9 NGAL, MMP9 TIMP1, NGAL, NSE, Progranulin, TUP, TGFB1, Thrombomodulin, sTNFR1, TPA, VEGF and Triglyceride, and / or the concentration of albumin / microalbumin / protein to creatinine in a sample isolated from a female patient, expressed as an albumin:creatinine ratio; and assessing the result and comparing it to a normal control, wherein an increase in the presence of the biomarkers compared to the normal control indicates the presence or risk of cancer in the patient from which the sample was isolated.

The present disclosure relates generally to novel compositions and methods for delivery of truncated midkine proteins in which the amino acid sequence encoded by exon 4 of human midkine is absent or partially absent and / or polynucleotides encoding said truncated human midkine proteins.

Embodiments of the present disclosure provide a method for treating developmental dysplasia of the hip. The method includes administering a therapeutically effective amount of a pharmaceutical composition to a subject suffering from the developmental dysplasia of the hip. The pharmaceutical composition includes a substance capable of inhibiting expression of Midkine (MDK), and the substance capable of inhibiting the expression of MDK is Midkine inhibitor (IMDK).

The invention relates to a new strategy for treating acute myelogenous leukemia, in particular to application of a midkine signaling pathway inhibitor in drugs for treating acute myelogenous leukemia. The invention provides application of a midkine signaling pathway as a target in preparation of drugs for preventing or treating acute myelogenous leukemia. A midkine inhibitor comprises iMDK or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable derivative thereof. The invention creatively discovers that the midkine inhibitor causes the apoptosis of acute myelogenous leukemia cells, so that a midkine signal channel is expected to become a drug target for treating acute myelogenous leukemia, and researches verify that the midkine antagonist can effectively relieve the development and deterioration of acute myelogenous leukemia. Therefore, a new strategy is provided for treatment of acute myelogenous leukemia.

Embodiments of the present disclosure provide a method for treating developmental dysplasia of the hip. The method includes administering a therapeutically effective amount of a pharmaceutical composition to a subject suffering from the developmental dysplasia of the hip. The pharmaceutical composition includes a substance capable of inhibiting expression of Midkine (MDK), and the substance capable of inhibiting the expression of MDK is Midkine inhibitor (IMDK).

The invention provides a Midkine-overexpressed mesenchymal stem cell, an extracellular vesicle and application of the Midkine-overexpressed mesenchymal stem cell and the extracellular vesicle. The mesenchymal stem cell is integrated with a gene element for overexpressing Midkine, the long-term survival and tissue chemotaxis ability of the mesenchymal stem cell are utilized to realize local continuous overexpression of Midkine recombinant protein, the engineered mesenchymal stem cell integrates the advantages of the Midkine recombinant protein and the mesenchymal stem cell, the synergistic effect of the Midkine recombinant protein and the mesenchymal stem cell is exerted, and the engineering mesenchymal stem cell has the advantages of promoting tissue regeneration and repair, promoting tissue regeneration and repairing and improving tissue regeneration and repair efficiency. Particularly, the method has huge potential in the aspects of cartilage tissue regeneration and skin wound repair; besides, the extracellular vesicles secreted by the Midkine-overexpressed mesenchymal stem cells contain Midkine recombinant protein or mRNA (messenger Ribonucleic Acid), and are also used for promoting cartilage injury repair.

An orally active, brain penetrant first-in-class small molecule midkine inhibitor for use in the treatment of triple-negative breast cancer, brain tumors (including glioblastoma, medulloblastoma, and NF1-mutant optic pathway gliomas), ovarian and endometrial cancers, lung cancer, as well as gynecologic non-malignant conditions such as endometriosis, uterine fibroids, and preterm birth, in which tumor cells and / or pathological cells exhibit heightened midkine signaling and express multiple midkine receptors.